

Study of DACHI Expression and its Epigenetic Regulators as Possible Breast Cancer-Related Biomarkers

Mohammad Hossein Nasirpour ¹, Mahdieh Salimi ^{1*}, Faezeh Majidi ², Zarrin Minucheher ³, and Hossein Mozdarani ⁴

1. Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
2. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
3. Institute of Industrial and Environmental Biotechnology (IIEB), National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
4. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Abstract

Background: Breast carcinogenesis involves both genetic and epigenetic changes. DNA methylation, as well as micro-RNA regulations, are the significant epigenetic phenomena dysregulated in breast cancer. Herein, the expression of *DACHI* as a tumor suppressor gene and its promoter methylation status was analyzed in breast cancer tumors. Also, the expression of three micro RNAs (miR-217, miR-6807-3p, and miR-552), which had been previously reported to target *DACHI*, was assessed.

Methods: The SYBR green-based Real-Time reverse transcription-PCR was used to determine *DACHI* and micro-RNAs (miR-217, miR-6807-3p, and miR-552) expression in 120 ductal breast cancer tumors compared with standard control. Also, the promoter methylation pattern of *DACHI* was investigated using the Methylation-specific PCR technique.

Results: *DACHI* expression was significantly down-regulated in breast tumors ($p < 0.05$). About 33.5% of tumors showed *DACHI* promoter hyper-methylation. The studied micro-RNAs, expression was negatively correlated with *DACHI* expression. The highest expressions of miRNAs and higher *DACHI* promoter methylation were observed in advanced cancer situations. The Kaplan-Meier survival curves indicated that the overall survival was significantly poor in higher miRNAs and lower *DACHI* expression in breast cancer patients ($p < 0.002$).

Conclusion: *DACHI* down-regulation may be associated with a poor breast cancer prognosis. The *DACHI* down-regulation may be due to epigenetic regulations such as promoter methylation, especially in triple-negative cases. Other factors, such as micro-RNAs (miR-217, miR-6807-3p, and miR-552), may also have an impact. The elevated expression of miR-217, miR-6807-3p, and miR-552, maybe candidates as possible poor prognostic biomarkers in breast cancer management for further consideration.

Keywords: Breast cancer, *DACHI*, Methylation, miR-217, miR-552, miR-6807-3p

To cite this article: Nasirpour MH, Salimi M, Majidi F, Minucheher Z, Mozdarani H. Study of *DACHI* Expression and its Epigenetic Regulators as Possible Breast Cancer-Related Biomarkers. Avicenna J Med Biotech 2023;15(2):108-117.

Introduction

Breast cancer is the second most common cause of cancer-related death and the most frequent cancer in women worldwide ¹. Despite advances in screening programs and better education that have led to a significant decline in breast cancer mortality, unfortunately, about 25-40% of breast cancers lead to metastases and death ¹. Unfavorable clinical results are primarily due to metastasis, therapy resistance, and tumor recurrence.

Identifying new biomarkers related to aggressive phenotypes, molecular subtypes, and prognosis of breast cancer is essential for drug development, proper treatment, disease surveillance, and cancer management. Therefore, understanding the molecular bases of such a diverse behavior of breast cancer subtypes and investigating novel and more effective therapeutic strategies is urgently needed ².

Epigenetic mechanisms such as DNA methylation, histone modifications, long non-coding RNA, and micro-RNA regulations have emerged as fundamental factors in breast cancer development and progression³. The epigenetic modifications are believed to be early events in breast cancer development due to their presence even in carcinoma *in situ* lesions, which makes them very suitable as early detection biomarkers⁴.

Dachshund family transcription factor 1, or *Dachshund homolog 1 (DACHI)*, as a critical cell fate determination factor, plays a vital role in breast cancer⁵. *DACHI* is expressed in normal human breast epithelium, while down-regulation of *DACHI* protein was found in many human breast cancers, significantly correlated with poor prognosis⁶. However, the reintroduction of *DACHI* indicatively reversed the transformed phenotype in these human mammary epithelial cells with some oncogenes^{6,7}. In previous studies, *DACHI* was reported to be epigenetically silenced in colorectal cancer and clear cell renal cell carcinoma^{8,9}. However, the mechanism underlying the frequent loss of *DACHI* in breast cancer has not been well explored yet.

In breast cancer, promoter hypermethylation has been reported in more than a hundred genes that most of them play essential roles in cell-cycle regulation, DNA repair, regulation of cell transcription, apoptosis, cell adhesion, hormone-mediated cell signaling, and tissue invasion and metastasis^{10,11}. In addition to hypermethylation, hypomethylation also represents a common feature of breast tumors and frequently occurs in regions of segmental duplications¹¹.

Several lines of evidence have demonstrated that the down-regulation of *DACHI* is closely associated with the proliferation, invasion, and metastasis of various tumors, including breast^{7,12}, lung¹³, esophageal cancer¹⁴, renal cell¹⁵, and hepatocellular carcinoma¹⁶. Micro-RNAs (miRNAs) are another main epigenetic element that has an essential role in gene regulation. The miRNAs are short (18-25 nucleotides), highly conserved non-coding RNAs, which perform a significant function in biological stability and gene expression at a post-transcriptional level by translation inhibition or degradation of protein-coding mRNAs *via* imperfect base-pairing to complementary sites on target mRNAs¹⁷.

The novel aspect of cancer studies comes from the fact that the micro RNAs can adjust the levels of their corresponding mRNAs and serve critical roles in the pathological and physiological processes of tumor development. The possibility that miRNA may be a novel focus for examining the current diagnosis and treatment of tumors has taken power¹⁷. The miR-552, miR-217, and miR-6807-3p are three miRNAs that have already been reported to directly target *DACHI* mRNA¹⁸⁻²⁰. About miR-217 and its association with cancer, conflicting results have been reported. Some studies have reported that down-regulation of miR-217 was strongly associated with tumor migration and invasion

in malignancies such as hepatocellular carcinoma²¹ and gastric cancer²². In contrast, it was reported that miR-217 promotes tumor proliferation in breast cancer by targeting *DACHI*¹⁹. Also, it inhibits triple-negative breast cancer cell growth, migration, and invasion by targeting *KLF5*²³.

MiR-552 is a newly discovered miRNA; its function and mechanism of action in biological processes and diseases are not entirely understood²⁴. Previous studies showed that miR-552 promotes colorectal cancer cell proliferation and migration by directly targeting *DACHI* *via* the Wnt/ β -catenin signaling pathway^{18,25}. The up-regulation of miR-552 was reported in ovarian cancer, especially in metastasis and recurrence²⁴. Also, miR-552 regulates liver tumor-initiating cell expansion and Sorafenib resistance²⁶. However, the role of miR-552 in breast cancer was little known.

Another micro-RNA studied in the present research is miR-6807-3p, which has been reported as a novel miRNA that promotes tumor-promoting influences on glioma progression by directly targeting *DACHI*²⁰. Here the *DACHI* expression and its possible epigenetics regulators focusing on its promoter methylations and expression of a panel of micro RNAs targeting *DACHI* (miR-217, miR-552, and miR-6807-3p) were studied in breast cancer patients.

Materials and Methods

Study population

This study was a case-control study. 120 tumor and standard adjacent tissue samples were obtained from breast ductal carcinoma females, and 40 samples of women with no cancer history underwent surgery due to mammoplasty. The samples were collected from the patients admitted to Imam-Khomeini Hospital (Tehran, Iran) between 2016 and 2017. The protocol was based on the Helsinki declaration, and patients and controls signed a written informed consent letter before enrollment (approval registered 52D/4922 dated 29 September 2016). Diagnosis of ductal carcinoma and availability of pathologic diagnostic information were considered inclusion, and receiving any chemo/radiotherapy before recruitment and any history of familial malignancy were considered exclusion criteria. The demographic and histochemical data of the patients and controls are summarized in table 1. Tumor staging was performed according to the Tumor, Node, and Metastasis (TNM) classification based on the American Joint Committee on Cancer (AJCC) staging system.

RNA and DNA extraction

Tissue samples (both tumor and normal) were immediately snap-frozen and stored at -70°C until use. Total RNA was extracted and purified from fresh-frozen biopsies with the RNX- Plus Kit (CinnaGen Co., Iran, EX6101), a guanidine/ phenol solution, for total RNA isolation from the homogenized sample. Through the action of guanidine salt in the RNA isolation procedure, DNA and protein were precipitated in

Table 1. Characteristics of breast cancer patients and controls

	Patient N (%)	Control N
Number	120	40
Age (years)		
Mean	47.8±10.54	40± 16.4
Range	23-82	22-70
Stage at diagnosis		
Stage I	20 (16.7%)	
Stage II	44 (36.7)	
Stage III	40 (33.3%)	
Stage IV	16 (13.3%)	
Lymph node status		
N0	50 (41.6%)	
N+	70(58.3%)	
Distant metastasis		
yes	16 [12 bone, 4 lung] (13.3%)	
No	104 (86.7%)	
Hormone receptor status (IHC)		
ER positive	94 (78.3%)	
ER negative	26 (21.7%)	
PR positive	92(76.7%)	
PR negative	28 (23.3%)	
HER-2 status (IHC/ CISH/FISH)		
+++	30 (25%)	
Negative	90(75%)	
Triple-negative breast cancer	14 (11.7%)	
Non-triple negative breast cancer	106 (88.3%)	

ER: the Estrogen Receptor, PR: Progesterone Receptor, HER2: Human Epidermal Growth Factor Receptor, LN: Lymph node, IHC: Immunohistochemistry, CISH: Chromogenic in-situ hybridization, FISH: Fluorescence *in situ* hybridization.

the phenol phase, and the aqueous phase contains high-quality all types of genomic RNA. DNA has been extracted by the manufacturer's protocol using a DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany, 69504). The RNA and DNA concentration and purity were confirmed using absorbance measurements with a NanoDrop 2000 (Thermo Scientific, USA).

Real-time reverse transcriptase (RT) -PCR

Real-time RT-PCR was performed to detect the expression levels of the *DACH1* gene and micro-RNAs (miR-217, miR-6807-3p, and miR-552) after cDNA synthesis using Precision qScript^T Reverse Transcription Kit (Primerdesign, Chandlers's Ford, UK, RT-NanoScript2) for mRNA expression and BonmiR cDNA kits (Bon biotech, Iran, BN-0011.17.2) for micro RNAs. All the steps were done according to the manufacturer's instructions. *Beta-actin* and *SNORD47* were used as the internal controls for *DACH1* and micro-RNAs, respectively. The primer sequences for *DACH1* and *beta-actin* were as follows: *DACH1*: F: 5' ATGTGGAACAAGTTCGCATCC 3' and R: 5' TGCA GTCATTGTAGAGGGTCT 3'; *Beta-actin*: F: 5' GAGACCTTCAACACCCAGC3' and R: 5' AGACGCA GGATGGCATGG 3'. All PCRs were performed using

a Light CyclerTM system (Rotor gene, Corbett, Germany). For each sample, 500 ng/ μ l of total cDNA was used. cDNA was mixed with 0.3 μ M of each forward and reverse primer with 10 μ l of SYBR green master mix (Roche, Germany, 4707516001) to a final reaction volume of 20 μ l. The thermal cycling conditions comprised an initial denaturation step at 95°C for 7 min and 45 cycles at 95°C for 10 s and 60°C for 30 s, and 72°C for 20 s. Experiments were performed with triplicates for each data point.

The primer set for micro-RNA expression analysis for designing and synthesis was ordered from Stem Cell Technology Company (Tehran, Iran). The ordered set comprised miR-217, miR-6807-3p, miR-552 specific forward primer, universal reverse primer, and internal control forward primer (*SNORD47*). The thermal cycling conditions consist of an initial denaturation step at 95°C for 2 min and 40 cycles at 95°C for 5 s and 60°C for 30 s. Amplification efficiency for each primer pair was determined by amplifying a standard linear curve (from 0.10 to 1,000 ng) of total cDNA assessed by an ultraviolet spectrophotometer. The standard curves have shown good linearity and amplification (approximately 100%). The expression level was calculated by the $2^{-\Delta\Delta CT}$ method. The data were presented as the fold change in gene expression normalized to an endogenous reference gene relative to the controls. The two-fold and more RNA expression is considered up-regulation, between 0.5- and 2-fold as usual and 0.5-fold and less as down-regulation.

Methylation-specific PCR (MS-PCR)

Bisulfite treatment of isolated DNA was performed using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany, 59104) according to the manufacturer's instructions. The methylation status of the *DACH1* gene was determined qualitatively by the Methylation-Specific Polymerase Chain Reaction (MS-PCR). Primer sequences used for MS-PCR analysis, with PCR product size and primer annealing temperature, are listed as follow: *DACH1* methylated-specific forward primer was 5'-GGAAAAATTATTAGTTTTTC GCGGAC-3' with the annealing temperature of 61.6°C, and reverse primer, 5'- AAACCGAAAA CACAAAATAACGA TC-3' with annealing temperature of 60°C, and *DACH1* un-methylated forward primer: 5'- TTTGGAA AAAATTATTAGTT TTTGTGGAT-3' with annealing temperature of 59.1°C, and reverse 5'- AAAAAAC-CAAAAACACAAAATAACAATCA-3' with annealing temperature of 59.8°C, the amplicon size was 130 base pair length. Four μ l of bisulfite-modified DNA were subjected to PCR amplification in a final reaction volume of 25 μ l comprised of 12.5 μ l of 2× EpiTect MSP Kit master mix (Qiagen, Hilden, Germany, 59305) and 0.5 μ M of each primer. PCR was performed with an initial 10 min of incubation at 95°C, followed by 40 cycles of denaturation, 30 s at 95°C, 30 s of annealing at 60°C, extension at 72°C for 60 s, and a final 10 min of hold at 72°C as a final extension

phase. Each sample was assessed in duplicate, and each run included no template control (NTC) and the EpiTek PCR control DNA set (methylated and unmethylated DNA) as external universal control (Qiagen, Hilden, Germany, 59655, 59665). Aliquots of PCR products were separated on 1.5% agarose gel, stained with ethidium bromide, and appeared under UV illumination.

Statistical analysis

Data were analyzed using SPSS 16.0 (SPSS Inc. Chicago, USA). The Mann-Whitney U test/Kruskal-Wallis test and the Chi-square test were performed for numerical and parametric data, respectively. Correlation and consistency were analyzed using Pearson correlation analysis. The Receiver Operating Characteristic (ROC) curve was used to illustrate diagnostic ability. Kaplan–Meier survival analysis was also performed. Numerical data are presented as the mean \pm Standard Deviation (SD). Differences were considered statistically significant if $p < 0.05$.

Results

mRNA expression levels of the *DACHI* gene

The mean relative expression of *DACHI* normalized with the *beta-actin* gene in breast tumor tissues was 0.17 ± 0.27 , indicating this gene's down-regulation compared with normal control groups. As shown in figure 1, the *DACHI* mRNA expression in breast cancer patients showed a wide range from 0.001 to 0.89 fold changes. The data revealed that about 12.5% of the patients showed normal *DACHI* expression, whereas most patients (about 82.5%) were *DACHI* gene down-regulated in breast tumors. As indicated in table 2, there was no statistically significant association between *DACHI* gene expression and Human Epidermal Growth factor Receptor 2 (HER2) or hormone receptor status (estrogen receptor, progesterone receptor) ($p > 0.05$). However, in the Triple-Negative (TN)




Figure 1. The Real-time RT-PCR analysis of *DACHI* mRNA expression in breast cancer tumors (T) and normal adjacent margin of the tumors (Nadj) compared with normal control (C). Results are expressed as fold number changed versus control. The *DACHI* RNA values were previously normalized to *beta-actin*.

breast tumors, the *DACHI* expression was significantly lower than the non-triple negative ones ($p = 0.0003$) as well as a significant decrease in *DACHI* expression was observed in metastatic and LN+ (lymph node involved) breast cancer cases ($p < 0.0001$). The data also indicated the significant down-regulation of the *DACHI* gene in the advanced stages of the disease (third and fourth stages) ($p = 0.0012$).

As shown in figure 2, the ROC curve analysis was performed between the breast cancer patients focusing on both the lymph nodal status (Figure 2A) and being (triple negative) TN or non-TN (Figure 2B). The ROC curve of *DACHI* expression for discriminating LN+ breast cancer patients from LN negatives had an area under the curve of 0.93 (95% confidence interval = 0.87-1) (Figure 2A), and for discriminating TN from non-TN breast cancer patients had the area under the curve of 0.89 (95% confidence interval = 0.80-0.98), (Figure 2B).

Table 2. The mRNA *DACHI* expression in breast cancer tumors is stratified according to the clinicopathological character

Various factors	Mean of <i>DACHI</i> exp. \pm SD	p-value	Statistical test	Significantly different ($p < 0.05$)
ER ⁺	0.15 \pm 0.25	p=0.7652	Mann-Whitney test	No
ER ⁻	0.20 \pm 0.29			
PR ⁺	0.14 \pm 0.27	p=0.2574	Mann-Whitney test	No
PR ⁻	0.19 \pm 0.27			
HER2 ⁺	0.21 \pm 0.29	p=0.2574	Mann-Whitney test	No
HER2 ⁻	0.20 \pm 0.30			
TN	0.003 \pm 0.002	p=0.0003	Mann-Whitney test	Yes
Non-TN	0.20 \pm 0.28			
LN ⁺	0.03 \pm 0.07	<math>p < 0.0001</math>	Mann-Whitney test	Yes
LN ⁻	0.38 \pm 0.32			
Stage I	0.35 \pm 0.29	0.0012	Kruskal-Wallis test	Yes
Stage II	0.18 \pm 0.28			
Stage III	0.02 \pm 0.02			
Stage IV	0.07 \pm 0.12			

ER: the Estrogen Receptor, PR: Progesterone Receptor, HER2: Human Epidermal Growth Factor Receptor, LN: Lymph Node, TN: Triple-Negative (ER-, PR-, HER2-).

DACH1 Epigenetic Regulation in Breast Cancer




Figure 2. The ROC curve of *DACH1* expression between the breast cancer patients discriminating both the lymph nodal status (Figure 2 a) and being TN or non-TN (Figure 2 b).

All patients were followed up for at least five years. The Overall Survival (OS) curves in lower and higher than mean *DACH1* expression groups were shown in figure 3A, and patients with lower *DACH1* expression displayed a poor OS ($p=0.0017$).

DACH1 gene promoter methylation status

The methylation status of breast tissues comprised of the tumor, normal adjacent, and normal control are summarized in table 3. The data indicated that 30% of breast tumors showed methylation of the *DACH1* promoter region, significantly higher than normal and normal adjacent control. Considering the frequency of the un-methylated promoter of the *DACH1* gene, which was 68.3%, it could be concluded that promoter methylation may not be the only factor that has an impact on the expression regulation of the *DACH1* gene.

About 86.7% of the normal tissues adjacent to the tumor were un-methylated in promoter regions of the *DACH1* gene. In comparison, 13.3% of the normal tissues adjacent to the tumor simultaneously showed a dual pattern, both methylated and non-methylated. The frequency of *DACH1* promoter methylation was assessed in different breast cancer patient groups based on clinicopathological characteristics, as shown in table 4. The data revealed that the highest frequency of *DACH1* promoter methylation was observed in poor prognostic cancer indicator groups, triple-negative and stage 4 with distant metastasis. There were no statistically significant differences between other clinicopathological characteristics such as being estrogen receptor positive or negative (ER+/ER-), progesterone receptor positive or negative (PR+/PR-), human epidermal growth factor receptor two positive or negative (HER2+, HER2-) or lymph-node involvement or not (LN+/LN-) ($p>0.05$).

Expression of *miR-217*, *miR-6807-3p*, and *miR-552* in the test and control groups

As shown in figure 4A, the expression levels of all three miRNAs (*miR-217*, *miR-6807-3p*, and *miR-552*) were significantly up-regulated in breast cancer patients compared with the control group ($p<0.0001$). There were no statically significant differences between normal adjacent and normal control groups in miRNAs expression (data are not shown). The expression of studied miRNAs was evaluated in different clinicopathological features of breast cancer patients in the study group. The experimental results revealed that *miR-217*, *miR-6807-3p*, and *miR-552* expression in the




Figure 3. Kaplan–Meier survival curves of breast cancer patients based on *DACH1* expression status ($p=0.0017$) (A) Kaplan–Meier survival curves of breast cancer patients based on the simultaneous expression of three studied miRNA (*miR-217*, *miR-6807-3p*, and *miR-552*) status ($p=0.0001$) (B).

Table 3. Categorization of *DACH1* promoter methylation status

Sample type	Total number	<i>DACH1</i> promoter methylated (%)	<i>DACH1</i> promoter un-methylated (%)	Both methylated and un-methylated promoter (%)	p-value χ^2 test
Breast Tumor	120	36 (30%)	82 (68.3%)	2(1.7%)	$p\leq 0.001$
Normal Adjacent	120	0 (0%)	104(86.7%)	16(13.3%)	$p\leq 0.001$
Normal Control	40	0 (0%)	40 (100%)	0 (0%)	$p\leq 0.001$

Table 4. *DACH1* promoter methylation status in different breast cancer groups based on hormone receptors status, lymph node involvement, and various stages of breast cancer

Various factors	Methylation status		Fisher's exact test	χ^2	Statistically significant (p<0.05)
	M, MU	U			
ER ⁺	28 (29.7%)	66 (70.3%)	p=0.7372	p=0.5518	No
ER ⁻	10 (38.5%)	16 (61.5%)			
PR ⁺	32 (34.8%)	60 (65.2%)	p=0.5146	p=0.3470	No
PR ⁻	6 (21.4%)	22 (78.57%)			
HER2 ⁺	10 (33.3%)	20 (66.7%)	p>0.9999	p=0.8727	No
HER2 ⁻	28 (31.1%)	62 (68.9%)			
TN	14(100%)	0 (0%)	p=0.0001	p<0.0001	Yes
Non-TN	24 (22.6%)	82 (77.4%)			
LN ⁺	22 (31.4%)	48 (68.6%)	p>0.9999	p=0.9626	No
LN ⁻	16 (32%)	34 (68%)			
Stage I	2 (10%)	18 (90%)			
Stage II	10 (22.7%)	34 (77.3%)		p=0.0001	Yes
Stage III	10 (25%)	30 (75%)			
Stage IV	16 (100%)	0 (0%)			

M: Methylated *DACH1* promoter, U: Un-methylated *DACH1* promoter, MU: Both methylated and Un-methylated *DACH1* promoters.




Figure 4. The Real-time RT-PCR analysis of three miRNAs (*miR-217*, *miR-6807-3p*, and *miR-552*) expression in breast cancer tumors compared with normal control (a), between different stages of the disease (b) and between LN-, and LN+ tumors (c). Results are expressed as fold number changed versus control. The *miRNA* values were previously normalized to *SNORD47*.

test group was related to higher stages of the disease and lymph nodal involvement, which are both considered poor prognosis indicators (p<0.0001, Figures 4B and C). The other factors, such as hormone and HER2 receptor status, were not positively associated with miRNA expression. The ROC curve analysis between studied miRNAs expression and lymph nodal involvement, focusing on the area under the curves, indicated the importance of miRNAs expression in metastasis (Figure 5). The negative correlation between the expression of *DACH1* and all three miRNAs (miR-217,

miR-6807-3p, and miR-552), $r = -0.99$, stated that the expression of the studied miRNAs (miR-217, miR-6807-3p, and miR-552) and *DACH1* gene is inversely related. All patients were followed up for at least five years. The OS curves in lower and higher than the mean expression of all three studied miRNA (miR-217, miR-6807-3p, and miR-552) groups were shown in figure 3B, and patients with higher simultaneous expression of three miRNAs displayed a poor OS (p=0.0001).

DACH1 Epigenetic Regulation in Breast Cancer




Figure 5. The ROC curve of miRNAs expression between the breast cancer patients discriminating the lymph nodal status, A) miR-552, B) miR-6807-3p, C) miR-217.

Discussion

The epigenetic dysregulation associated with genetic alterations is a component of breast cancer. The genomic instability due to epigenetic pathogenesis is central to breast cancer hallmarks. Being plastic and reversible, epigenetic processes appear more amenable to therapeutic intervention than the more unidirectional genetic aberrations²⁷. *DACH1* plays a vital role in the natural evolution of several organs as a member of the Retinal Determination Gene Network (RDGN), consisting of other genes such as *EYAI* and *SIX1*. The *DACH1* gene acts as a tumor suppressor, and its reduced expression can lead to cancer²⁸. Many observations have shown that down-regulation of the *DACH1* gene leads to the proliferation of cancer cells, invasion, and metastasis in a variety of malignancies, including mammary^{7,12,29}, lung¹³, esophageal¹⁴, renal¹⁵, and liver¹⁶ tumors. There is strong evidence that nuclear *DACH1* expression can act as a tumor suppressor gene. Nuclear *DACH1* protein expression was significantly associated with markers of good prognosis, including low cell proliferation (*MIB1* expression) and functional apoptosis (*Bcl2* expression). It has previously been observed that reduced *DACH1* expression occurs in invasive breast cancer³⁰. This finding was confirmed by our data, where *DACH1* face showed an inverse association with poor prognosis indicators such as nodal and distant metastasis and higher cancer stages.

More recently, it was reported that *DACH1* inhibited the invasion and metastasis of breast cancer cells by decreasing MMP9 expression. Regarding mechanism, *DACH1* interacted with p65 and c-Jun at the NF- κ B and AP-1 binding sites, respectively. Moreover, *DACH1* reduced the acetylation level of p65 by recruiting HDAC1 and then repressed the transcriptional activity of p65⁷. Further evidence of its tumor suppressor gene function is that *DACH1* homozygous deletion stimulates tumorigenesis in glioma cells³¹, and loss of *DACH1* occurs in the high FIGO surgical stage endometrial cancers³². *DACH1* represses steroid hormone signaling by interacting with hormone receptors, including ER and androgen^{33,34}. Cytoplasmic *DACH1* expression levels also correlated to several clinico-

pathological parameters, including histologic grade, FIGO surgical score, and pathological type. Again, cytoplasmic expression of *DACH1* was more prevalent in higher-grade tumors like G2-3/G3 versus G1 to G2 and stage III to IV versus stage I to II³⁵. Moreover, the nuclear expression of *DACH1* in ovarian cancer correlated with histologic grade and FIGO surgical stage. Finally, a comparison between the expression of *DACH1* and one of the major players in ovarian cancer, ER+, revealed that *DACH1* localization was preferentially cytoplasmic in the ER-positive ovarian cancer samples³⁵. Additionally, *DACH1* has been identified to inhibit the transforming growth factor- β CRC signaling pathway in ovarian and breast cancer³⁶ and to restrain the Wnt/ β -catenin signaling pathway in Colorectal Cancer (CRC)¹⁵. Also, it affects the PI3K/AKT signaling pathway, a vital kinase cascade that plays a role in the regulation of cellular quiescence, proliferation, cancer, and longevity³⁷, and its disruption can lead to tumorigenesis.

The Wnt/ β -catenin pathway, as an evolutionarily conserved pathway, is essential in initiating and regulating a diverse range of cellular activities, including calcium homeostasis, cell proliferation, and cell polarity³⁸. Several target proteins are in the Wnt/ β -catenin signaling pathway, including cyclin D, c-Myc, MMP3, and LEF. Previous studies have revealed that *DACH1* exhibited an inverse correlation with cyclin D1 and c-Myc⁸. It was reported that *DACH1* might exert inhibitory effects on the development of breast cancer partly by suppression of EMT inducers and CSCs markers, especially *CD44*⁵.

This study showed that the expression of the *DACH1* gene in tumor tissue was significantly reduced compared to its typical adjacent normal breast tissues and normal control. In fact, in 82.5% of tumor tissues, there was a reduction in *DACH1* gene expression. These data confirm the possible role of the *DACH1* gene as a tumor suppressor. Although tumors are caused by the accumulation of a series of genetic changes, the formation of tumors is not only limited to genetic differences, epigenetic changes could also contribute to this phenomenon. Epigenetics is a mecha-

nism for the stable maintenance of gene expression that involves physically 'marking' DNA or its associated proteins, which allows genotypically identical cells to be phenotypically different³⁹. Epigenetic marking of the genome has several forms. Acetylation, phosphorylation, ubiquitylation, and methylation of histones and DNA methylation are potential mechanisms for the epigenetic tagging of the genome^{40,41}. DNA methylation, as the most prominent epigenetic marker, refers to adding a methyl (CH₃) group on the cytosine arm in the genome-rich CpG nucleotide regions known as CpG islands⁴². Studies have shown that hypermethylation in the CpG islands in the promoter regions of tumor suppressor genes prevents them from being expressed and thus can promote carcinogenesis²⁷.

In the present study, the data revealed that about 32% of the breast tumor samples had methylation in the promoter region of the *DACH1* gene. However, in the normal adjacent tissues (average margin of the tumor), about 87% of the cases lacked methylation in the promoter region of this gene, and about 13% of the cases simultaneously yielded both bands corresponding to methylated and non-methylated promoters. Methylation of the *DACH1* gene promoter was not observed in normal breast tissue extracted from women who underwent cosmetic surgery.

Based on histopathological characteristics, the study of *DACH1* promoter methylation frequency in different groups of breast cancer patients indicated a positive association between *DACH1* promoter methylation and distant metastasis and triple negative hormone receptor status ($p < 0.001$). In this study, the association between the higher stages of breast cancer and the more significant methylation of the *DACH1* gene was observed, which suggests further suppression of this tumor suppressor in the advanced stages of cancer.

It could be concluded that *DACH1* as a tumor suppressor gene may have a role in breast cancer induction, but the reduction of *DACH1* gene expression does not seem to be solely due to the promoter's methylation. According to several previous reports, interactions between miRNAs and their corresponding mRNA regulate the expression of proto-oncogenes or tumor suppressor genes⁴³ and determine the malignant characteristics of tumor cells, and were involved in almost every step during the initiation, development, and progression of breast cancer⁴⁴.

Numerous studies have reported miRNA dysregulation in cancerous cell growth and proliferation, cell death inhibition, immune invasion, neoangiogenesis, and metastasis⁴⁵. Also, miRNAs regulate the fate of cancer stem cells (CSCs)²⁷. The cancer miRNA dysregulation may result from the alteration of epigenetic and genetic regulation of the miRNA genes, aberrant miRNA biogenesis, and disruption of miRNA transcriptional control⁴⁵. The copy number variation due to the amplification or deletion of miRNA genes, arising from the cancer-associated genomic instability, the hy-

permethylation of CpG islands near the miRNA genes, and epigenetic drugs have been reported to alter the expression profile of miRNAs⁴⁶. It was reported that miRNA dysregulation is associated with the progression through every stage of breast cancer to metastasis²⁷. Also, miRNAs provide notable information for breast cancer diagnosis, subtyping, prognosis, and treatment monitoring²⁷.

In the present study, the expression of miR-217, miR-6807-3p, and miR-552, the three miRNAs which had been already reported to target *DACH1* directly, were studied¹⁸⁻²⁰. The present data revealed that the expression of the three miRNAs (miR-217, miR-6807-3p, and miR-552) was significantly upregulated in breast cancer tumors compared with normal control. Notably, these data indicate that high expression of these miRNAs was associated with the proliferation and migration of breast cancer. The present study may explain the role of miR-217, miR-6807-3p, and miR-552 in breast cancer.

Previous studies confirmed our findings in several cancers. For instance, increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer by directly targeting *DACH1*. In addition, miR-552 also enhances the metastatic capacity of colorectal cancer cells by targeting metalloprotease and disintegrin 28. It was also reported that miR-552 over-expression correlated well with the poor prognosis of ovarian cancer patients²⁴.

miR-217 was reported as a novel onco-miR in breast cancer. It could accelerate the cell cycle progression by directly targeting the *DACH1* gene and inhibiting its anti-cancer functions and proposed inhibiting miR-217 as a potent therapeutic strategy for breast cancer¹⁹. In contrast, in renal cell carcinoma, the lower expression of miR-217 was reported to be associated with higher tumor grade and stage and stated that the down-regulated expression of miR-217 was associated with tumor development and metastasis²².

miR-6807-3p was reported as a new miRNA that promoted cell proliferation and migration, inhibited apoptosis in glioma cells, and served as an oncogene in a miR-217-5p-independent manner in glioma. It was reported that miR-6807-3p could be an essential tumor facilitator in vitro. *DACH1* was registered as a target molecule of miR-6807-3p²⁰.

Conclusion

The data indicate that reducing *DACH1* gene expression may be associated with a poor breast cancer prognosis. This reduction may be due to epigenetic regulations such as promoter hypermethylation, especially in triple-negative cases, and micro-RNAs (miR-217, miR-6807-3p, and miR-552) up-regulation. The data revealed that higher expression of the studied micro-RNAs (miR-217, miR-6807-3p, and miR-552) may be considered poor prognosis possible biomarkers in breast cancer management.

Acknowledgement

We sincerely thank all the individuals who participated in this study. This project was supported by the National Institute of Genetic Engineering and Biotechnology (NIGEB) (Grant number is 961202-I-651, ethical registration code is 52D/4922 dated 29 September 2016).

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70(1):7-30.
2. Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. *Semin Cancer Biol* 2018;51:22-35.
3. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. *Dev Cell* 2010;19(5):698-711.
4. He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, et al. miRNA-based biomarkers, therapies, and resistance in Cancer. *Int J Biol Sci* 2020;16(14):2628-47.
5. Xu H, Yu S, Yuan X, Xiong J, Kuang D, Pestell RG, et al. DACH1 suppresses breast cancer as a negative regulator of CD44. *Sci Rep* 2017;7(1):4361.
6. Wu K, Liu M, Li A, Donninger H, Rao M, Jiao X, et al. Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. *Mol Biol Cell* 2007;18(3):755-67.
7. Aman S, Li Y, Cheng Y, Yang Y, Lv L, Li B, et al. DACH1 inhibits breast cancer cell invasion and metastasis by down-regulating the transcription of matrix metalloproteinase 9. *Cell Death Discov* 2021 Nov 12;7(1):351.
8. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, et al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. *Epigenetics* 2013; 8(12):1373-83.
9. Dalgin GS, Drever M, Williams T, King T, DeLisi C, Liou LS. Identification of novel epigenetic markers for clear cell renal cell carcinoma. *J Urol* 2008;180(3):1126-30.
10. Shukla S, Penta D, Mondal P, Meeran SM. Epigenetics of breast cancer: clinical status of epi-drugs and phytochemicals. *Adv Exp Med Biol* 2019;1152:293-310.
11. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. *Cancer Res* 2008; 8(20):8616-25.
12. Zhao F, Wang M, Li S, Bai X, Bi H, Liu Y, et al. DACH1 inhibits SNAIL-mediated epithelial-mesenchymal transition and represses breast carcinoma metastasis. *Oncogenesis* 2015;4(3):e143.
13. Feng Y, Wang L, Wang M. Alteration of DACH1 methylation patterns in lung cancer contributes to cell proliferation and migration. *Biochem Cell Biol* 2018;96(5): 602-9.
14. Wu L, Herman JG, Brock MV, Wu K, Mao G, Yan W, et al. Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF- β signaling. *PLoS One* 2014; 9(4):e95509.
15. Chu Q, Han N, Yuan X, Nie X, Wu H, Chen Y, et al. DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. *J Hematol Oncol* 2014 7:73.
16. Liu Y, Zhou R, Yuan X, Han N, Zhou S, Xu H, et al. DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/ β -catenin signaling. *Oncotarget* 2015;6(11):8621-34.
17. Loh HY, Norman BP, Lai KS, Rahman NMANA, Alithdeen NBM, Osman MA. The regulatory role of microRNAs in breast cancer. *Int J Mol Sci* 2019;0(19): 4940.
18. Cao J, Yan XR, Liu T, Han XB, Yu JJ, Liu SH, et al. MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/ β -catenin signaling pathway in colorectal cancer. *Oncol Lett* 2017;14(3):3795-3802.
19. Zhang Q, Yuan Y, Cui J, Xiao T, Jiang D. MiR-217 oromotes tumor oroliferation in breast cancer via targeting DACH1. *J Cancer* 2015;6(2):184-91.
20. Lu GF, Geng F, Xiao Z, Chen YS, Han Y, You CY, et al. MicroRNA-6807-3p promotes the tumorigenesis of glioma by targeting downstream DACH1. *Brain Res* 2019; 1708:47-57.
21. Su J, Wang Q, Liu Y, Zhong M. miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. *Mol Cell Biochem* 2014;392(1-2):289-96.
22. Chen G, Yang Z, Feng M, Wang Z. microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer. *Biosci Rep* 2020;40 (1):BSR20193176.
23. Zhou W, Song F, Wu Q, Liu R, Wang L, Liu C, et al. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5. *PLoS One* 2017;12(4):e0176395.
24. Zhao W, Han T, Li B, Ma Q, Yang P, Li H. miR-552 promotes ovarian cancer progression by regulating PTEN pathway. *J Ovarian Res* 2019;12(1):121.
25. Barati N, Tafrihi M, A Najafi SM. Membrane localization of β -catenin in prostate cancer PC3 cells treated with *Teucrium persicum* Boiss. extract. *Nutr Cancer* 2021;74 (5): 1819-28.
26. Han T, Zhang Y, Yang X, Han L, Li H, Chen T, et al. miR-552 regulates liver tumor-initiating cell expansion and sorafenib resistance. *Mol Ther Nucleic Acids* 2020; 19:1073-85.
27. Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and epigenetics strategies to reverse breast cancer. *Cells* 2019;8(10):1214.
28. Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, et al. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. *Cancer Res* 2014;74 (3):829-39.

29. Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, et al. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. *PLoS One* 2014;9(1):e84428.
30. Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, et al. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. *Mol Cell Biol* 2006; 26(19):7116-29.
31. Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D, et al. Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. *Proc Natl Acad Sci USA* 2011;108(30):12384-9.
32. Riggs MJ, Lin N, Wang C, Piccoro DW, Miller RW, Hampton OA, et al. DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. *PLoS One* 2020;15(12):e0244558.
33. Popov VM, Zhou J, Shirley LA, Quong J, Yeow WS, Wright JA, et al. The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. *Cancer Res* 2009;69(14):5752-60.
34. Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, Song LN, et al. The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. *Cancer Res* 2009;69(8):3347-55.
35. Liang F, Lü Q, Sun S, Zhou J, Popov VM, Li S, et al. Increased expression of dachshund homolog 1 in ovarian cancer as a predictor for poor outcome. *Int J Gynecol Cancer* 2012;22(3):386-93.
36. Wang P. Suppression of DACH1 promotes migration and invasion of colorectal cancer via activating TGF- β -mediated epithelial-mesenchymal transition. *Biochem Biophys Res Commun* 2015;460(2):314-9.
37. Haga S, Ozaki M, Inoue H, Okamoto Y, Ogawa W, Takeda K, et al. The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. *Hepatology* 2009;49(1):204-14.
38. Wen X, Wu Y, Awadasseid A, Tanaka Y, Zhang W. New advances in canonical Wnt/ β -catenin signaling in cancer. *Cancer Manag Res* 2020;12:6987-98.
39. Zhang L, Lu Q, Chang C. Epigenetics in health and disease. *Adv Exp Med Biol* 2020;1253:3-55.
40. Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. *Gastroenterology* 2021;160(3): 690-709.
41. Dumitrescu RG. Interplay between genetic and epigenetic changes in breast cancer subtypes. *Methods Mol Biol* 2018;1856:19-34.
42. Köhler F, Rodríguez-Paredes M. DNA methylation in epidermal differentiation, aging, and cancer. *J Invest Dermatol* 2020;140(1):38-47.
43. Jiang D, Xie X, Lu Z, Liu L, Qu Y, Wu S, et al. Establishment of a colorectal cancer-related microRNA-mRNA regulatory network by microarray and bioinformatics. *Front Genet* 2020;11:560186.
44. Abdalla F, Singh B, Bhat HK. MicroRNAs and gene regulation in breast cancer. *J Biochem Mol Toxicol* 2020; 34(11):e22567.
45. Peng Y, Croce CM. The role of MicroRNAs in human cancer. *Signal Transduct Target Ther* 2016;1:15004.
46. Lee YS, Dutta A. MicroRNAs in cancer. *Annu Rev Pathol* 2009;4:199-227.